CClinicalTrials.gg
CompletedNCT03284567FFABCUpdated Oct 1, 2021

Football Fitness After Breast Cancer

An interventional study of Football fitness in Breast Neoplasm Female, sponsored by University of Copenhagen. Completed at 1 site in Denmark. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-10-01.

Sponsored by University of Copenhagen · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

Late effects of breast cancer treatment are widely reported including deteriorating fitness, fatigue, loss of muscle and bone mass, and increased body fat percentage. Exercise interventions may ameliorate a number of these effects including fatigue, fitness and improve quality of life. However only limited knowledge exists on the potential of novel interventions and settings, such as sports outside the hospital setting, to improve late effects of breast cancer treatment. The 'Football Fitness After Breast Cancer' (FF ABC) study is a randomized trial comparing the effects of a football training intervention with standard treatment approaches on fitness, bone mineralization, body composition, muscle strength, blood pressure, and patient-reported outcomes in women treated for breast cancer.

02

Conditions studied

  • Breast Neoplasm Female

Browse trials for

Keywords

  • Breast cancer
  • Football
  • Late effects
  • Physical exercise
  • Soccer training
  • Rehabilitation
  • Bone mineralization
  • Body composition
  • Fitness
  • Aerobic capacity
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Women surgically managed for breast cancer, local and regional advanced breast cancer.
  • Completion of adjuvant chemotherapy and radiation therapy.
  • Legally competent persons with ability to read and understand Danish.
  • Signed informed consent.
  • Performance level 0-1 (WHO).

Exclusion criteria

Exclusion Criteria:

  • WHO performance level > 1.
  • Osteoporosis (T-score \< -2.5).
  • Known metastatic breast cancer (stage IV).
  • Women in DBCG-group I (age => 60 years, tumor =\< 10 mm, invasive ductal carcinoma grade I, invasive lobular carcinoma grade I / II, estrogen receptor positive and HER2 normal).
  • Cardiovascular or pulmonary disorders (e.g., arrhythmias, ischemic heart disease, unregulated high blood pressure, chronic obstructive lung disease).
  • Ongoing anticoagulant therapy (vitamin K antagonists; Marevan, Marcoumar and low molecular weight heparins; Innohep, Clexane, Fragmin) for pulmonary embolism or deep venous thrombosis (DVT) due to increased bleeding risk of falls and clashes with other players during exercise.
  • Current or scheduled chemotherapy and radiation therapy in the intervention period (12 months).
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Active comparator
    Football fitness

    Participants in the intervention group will practice soccer for 52 weeks two times weekly. A soccer instructor will be in charge of all training sessions. The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games. Training will take place on a natural grass pitch. In adverse weather conditions (i.e., \< 5°C or heavy rain) training will be performed indoors. Participants will be told to avoid hard tackles and other actions that carry a risk of injury.

    Behavioral: Football fitness

  • No intervention
    Control group

    Participants in the control group will receive verbal advice about the benefits of exercise and physical activity.

Interventions

  • BehavioralFootball fitness

    The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games. Training will take place on a natural grass pitch. In adverse weather conditions (i.e., \< 5°C or heavy rain) training will be performed indoors

05

What researchers measure

Primary outcomes

  1. Mean change in fitness level (maximal oxygen uptake) from baseline to month 6 and month 12.

    Incremental test to exhaustion on a cycle ergometer.

    Time frame: 6 months and 12 months.

Secondary outcomes

  1. Mean change in whole-body fat mass from baseline to month 6 and month 12.

    Assessed by dual energy x-ray absorptiometry.

    Time frame: 6 months and 12 months.

  2. Mean change in whole-body weight from baseline to month 6 and month 12.

    Body weight was measured with a digital platform scale.

    Time frame: 6 month and 12 month.

  3. Mean change in whole-body muscle mass from baseline to month 6 and month 12.

    Assessed by dual energy x-ray absorptiometry.

    Time frame: 6 month and 12 month.

  4. Mean change in muscle strength from baseline to month 6 and month 12.

    Dynamic concentric muscle strength for the knee extensors (1RM).

    Time frame: 6 month and 12 month.

  5. Mean change in balance from baseline to month 6 and month 12.

    Single-leg flamingo balance test.

    Time frame: 6 month and 12 month.

  6. Mean change in blood pressure from baseline to month 6 and month 12.

    Blood pressure will be measured with a digital sphygmomanometer.

    Time frame: 6 month and 12 month.

  7. Mean change in markers of bone mineral metabolism from baseline to month 6 and month 12.

    Procollagen type I C propeptide, osteocalcin and C-terminal telopeptide will be analyzed by a chemiluminescence method using a fully automated immunoassay system (iSYS, Immunodiagnostic Systems Ltd., Boldon, England.

    Time frame: 6 month and 12 month.

  8. Mean change in cholesterol from baseline to month 6 and month 12.

    Blood samples will be analyzed at baseline, 6 and 12 month for total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and glycosylated hemoglobin, respectively, by automated analyzers (Cobas Fara, Roche, Neuilly sur Seine, France) using enzymatic kits (Roche Diagnostics, Mannheim, Germany, and Tosoh G7, Tosoh Europe, Tessenderlo, Belgium).

    Time frame: 6 month and 12 month.

  9. Self-reported physical activity from baseline to month 6 and month 12.

    Assessed by the International Physical Activity Questionnaire (IPAQ).

    Time frame: 6 month and 12 month.

  10. Self-reported diagnosis-specific symptoms and side-effects from baseline to month 6 and month 12.

    Assessed by the supplement EORTC QLQ-BR23.

    Time frame: 6 month and 12 month.

  11. Self-reported health-related quality of life outcomes from baseline to month 6 and month 12.

    Assessed by the 15 subscales of the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30).

    Time frame: 6 month and 12 month.

  12. Self-reported functional level in upper extremities from baseline to month 6 and month 12.

    Assessed by disabilities of the arm, shoulder and hand (DASH).

    Time frame: 6 month and 12 month.

  13. Self-reported health related quality of life from baseline to month 6 and month 12.

    Assessed by The Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36)

    Time frame: 6 month and 12 month.

  14. Mean change in bone mineral density (BMD) of the spine (L2-L4), Total hip and Femoral Neck.

    Assessed by dual energy x-ray absorptiometry.

    Time frame: 6 month and 12 month.

  15. Mean change in total body and leg bone mineral content (BMC).

    Assessed by dual energy x-ray absorptiometry.

    Time frame: 6 month and 12 month.

06

Study locations

1 site
  • University Hospital of Copenhagen, Rigshospitalet
    Copenhagen, 2100, Denmark
07

References and documents

Publications

  • Bloomquist K, Krustrup P, Fristrup B, Sorensen V, Helge JW, Helge EW, Soelberg Vadstrup E, Rorth M, Hayes SC, Uth J. Effects of football fitness training on lymphedema and upper-extremity function in women after treatment for breast cancer: a randomized trial. Acta Oncol. 2021 Mar;60(3):392-400. doi: 10.1080/0284186X.2020.1868570. Epub 2021 Jan 11. PubMed 33423594 ↗
  • Uth J, Fristrup B, Sorensen V, Helge EW, Christensen MK, Kjaergaard JB, Moller TK, Mohr M, Helge JW, Jorgensen NR, Rorth M, Vadstrup ES, Krustrup P. Exercise intensity and cardiovascular health outcomes after 12 months of football fitness training in women treated for stage I-III breast cancer: Results from the football fitness After Breast Cancer (ABC) randomized controlled trial. Prog Cardiovasc Dis. 2020 Nov-Dec;63(6):792-799. doi: 10.1016/j.pcad.2020.08.002. Epub 2020 Aug 12. PubMed 32800792 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03284567
Lead sponsor
University of Copenhagen
Collaborators
University of Southern Denmark
Responsible party
Jacob Uth (Postdoc, University of Copenhagen) — Principal investigator
First posted
Sep 15, 2017
Start date
Mar 20, 2017
Primary completion
Nov 30, 2019
Completion
Jan 20, 2020
Last update
Oct 1, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion